These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10725065)

  • 21. The use of Sandimmun (cyclosporin A) in severe refractory rheumatoid arthritis: the Belgian experience.
    Malaise MG; De Keyser P; De Backer M; van Lierde MA; Lesaffre E
    Clin Rheumatol; 1995 Sep; 14 Suppl 2():26-32. PubMed ID: 8846651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
    Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL
    Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Sandimmun-Neoral--a new quality of life for patients with severe systemic juvenile rheumatoid arthritis].
    Alekseeva EI; Shakhbazian IE
    Ter Arkh; 1999; 71(5):26-9. PubMed ID: 10399226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Passage from sandimmun to neoral in kidney transplantation in children].
    Broyer M; Maisin A; Guest G; Baudouin V; Charbit M; Reigneau O; Loirat C
    Arch Pediatr; 1999 Oct; 6(10):1066-9. PubMed ID: 10544781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical use of cyclosporin in rheumatoid arthritis.
    Richardson C; Emery P
    Drugs; 1995; 50 Suppl 1():26-36. PubMed ID: 8714796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin.
    Gulliver WP; Murphy GF; Hannaford VA; Primmett DR
    Br J Dermatol; 1996 Sep; 135 Suppl 48():35-9. PubMed ID: 8881903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy, tolerability and safety of cyclosporine for microemulsion in the treatment of active rheumatoid arthritis. Open study].
    Marcos JC; Maccagno A; Gutfraind E; Garsd A; Messina DO; Maldonado Cocco J; Battagliotti C; Onetti CM; Tate G; Venarotti HO; Grosman H; Díaz EA; Otero AB
    Medicina (B Aires); 2000; 60(4):435-40. PubMed ID: 11188947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the steady state pharmacokinetics of two formulations of cyclosporin in patients with atopic dermatitis.
    Chawla M; Ali M; Marks R
    Br J Dermatol; 1996 Sep; 135 Suppl 48():9-14. PubMed ID: 8881898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioavailability of Sandimmun® versus Sandimmun Neoral®: a meta-analysis of published studies.
    Colombo D; Egan CG
    Int J Immunopathol Pharmacol; 2010; 23(4):1177-83. PubMed ID: 21244766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety and efficacy of cyclosporine (Neoral) in rheumatoid arthritis.
    Johns KR; Littlejohn GO
    J Rheumatol; 1999 Oct; 26(10):2110-3. PubMed ID: 10529125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine.
    van den Borne BE; Landewé RB; Goei The HS; Rietveld JH; Zwinderman AH; Bruyn GA; Breedveld FC; Dijkmans BA
    J Rheumatol; 1998 Aug; 25(8):1493-8. PubMed ID: 9712089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients.
    Bistrup C; Nielsen FT; Jeppesen UE; Dieperink H
    Nephrol Dial Transplant; 2001 Feb; 16(2):373-7. PubMed ID: 11158415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoral (cyclosporin) in dermatology: technical aspects.
    Smith SG
    Br J Dermatol; 1996 Sep; 135 Suppl 48():2-4. PubMed ID: 8881896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic equivalence and mg:mg switch ability of a generic cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients maintained on Sandimmun Neoral.
    Al Wakeel JS; Shaheen FA; Mathew MC; Abouzeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
    Transplant Proc; 2008 Sep; 40(7):2252-7. PubMed ID: 18790206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new microemulsion formulation of cyclosporin (Neoral) is effective in the treatment of cyclosporin-resistant dermatoses.
    Bourke JF; Berth-Jones J; Holder J; Graham-Brown RA
    Br J Dermatol; 1996 Apr; 134(4):777-9. PubMed ID: 8733391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)].
    Wakasugi H; Yoshimoto M; Ono T; Muso E; Inui K
    Nihon Jinzo Gakkai Shi; 2002 Dec; 44(8):792-7. PubMed ID: 12607968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. UK multicentre study to assess the safety and tolerability of Neoral in stable renal transplant patients. UK Neoral Study Group.
    Moore RH
    Transpl Int; 1996; 9 Suppl 1():S311-3. PubMed ID: 8959853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Variability of the bioavailability of cyclosporine: benefit of the Neoral formulation].
    Humbert H
    Therapie; 1997; 52(4):353-7. PubMed ID: 9437891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria.
    Fu LW; Yang LY; Chen WP; Lin CY
    Br J Rheumatol; 1998 Feb; 37(2):217-21. PubMed ID: 9569080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advantages of Neoral conversion in renal transplant patients.
    Vennarecci G; Pisani F; Tisone G; Buonomo O; Famulari A; Casciani CU
    Minerva Urol Nefrol; 1998 Jun; 50(2):161-4. PubMed ID: 9707972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.